These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1797455)

  • 1. Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
    Jones RN; Gerlach EH; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME; Knapp CC
    Diagn Microbiol Infect Dis; 1991; 14(5):383-8. PubMed ID: 1797455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.
    Jones RN; Fuchs PC; Washington JA; Gavan TL; Murray PR; Gerlach EH; Thornsberry C
    Diagn Microbiol Infect Dis; 1990; 13(6):499-507. PubMed ID: 2126232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.
    Jones RN; Gavan TL; Thornsberry C; Fuchs PC; Gerlach EH; Knapp JS; Murray P; Washington JA
    J Clin Microbiol; 1989 Dec; 27(12):2758-66. PubMed ID: 2531756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan.
    Jones RN; Gerlach EH; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME; Knapp CC
    J Clin Microbiol; 1991 Feb; 29(2):363-6. PubMed ID: 1901067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
    Jones RN; Erwin ME; Washington JA; Koontz FP; Murray PR; Gerlach EH
    Diagn Microbiol Infect Dis; 1992; 15(7):627-32. PubMed ID: 1424520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.
    Barrett MS; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):243-5. PubMed ID: 8112036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.
    Fuchs PC; Barry AL; Baker C; Murray PR; Washington JA
    J Clin Microbiol; 1991 Oct; 29(10):2111-4. PubMed ID: 1939563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
    Pfaller MA; Jones RN; Washington JA; Koontz FP; Gerlach EH; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):145-50. PubMed ID: 1315231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed interpretive criteria and quality control parameters for ofloxacin susceptibility testing of Neisseria gonorrhoeae.
    Fuchs PC; Barry AL; Baker C; Murray PR; Washington JA
    J Clin Microbiol; 1992 Apr; 30(4):1024-6. PubMed ID: 1572960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.
    Erwin ME; Jones RN; Koontz FP; Gerlach EH; Murray PR; Washington JA
    J Clin Microbiol; 1992 May; 30(5):1317-9. PubMed ID: 1316371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection.
    Plourde PJ; Tyndall M; Agoki E; Ombette J; Slaney LA; D'Costa LJ; Ndinya-Achola JO; Plummer FA
    J Infect Dis; 1992 Oct; 166(4):919-22. PubMed ID: 1527431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence and Spread of Neisseria gonorrhoeae Isolates With Decreased Susceptibility to Extended-Spectrum Cephalosporins in Argentina, 2009 to 2013.
    Gianecini R; Romero MLM; Oviedo C; Vacchino M; Galarza P;
    Sex Transm Dis; 2017 Jun; 44(6):351-355. PubMed ID: 28499284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.
    Kirkcaldy RD; Harvey A; Papp JR; Del Rio C; Soge OO; Holmes KK; Hook EW; Kubin G; Riedel S; Zenilman J; Pettus K; Sanders T; Sharpe S; Torrone E
    MMWR Surveill Summ; 2016 Jul; 65(7):1-19. PubMed ID: 27414503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.
    Doern GV; Jones RN; Gerlach EH; Hindler J; St Amand R
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):481-9. PubMed ID: 7957268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010.
    Carannante A; Prignano G; Cusini M; Matteelli A; Dal Conte I; Ghisetti V; D'Antuono A; Cavrini F; Antonetti R; Stefanelli P
    Clin Microbiol Infect; 2012 Jun; 18(6):558-64. PubMed ID: 21966997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010.
    Martin I; Sawatzky P; Allen V; Hoang L; Lefebvre B; Mina N; Wong T; Gilmour M
    Sex Transm Dis; 2012 Apr; 39(4):316-23. PubMed ID: 22421701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefixime disk susceptibility test criteria.
    Fuchs PC; Barry AL; Jones RN
    J Clin Microbiol; 1986 Oct; 24(4):647-9. PubMed ID: 3771755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a 'susceptible' Neisseria gonorrhoeae population.
    Thakur SD; Starnino S; Horsman GB; Levett PN; Dillon JR
    J Antimicrob Chemother; 2014 Jun; 69(6):1510-6. PubMed ID: 24532681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.
    Ison CA; Town K; Obi C; Chisholm S; Hughes G; Livermore DM; Lowndes CM;
    Lancet Infect Dis; 2013 Sep; 13(9):762-8. PubMed ID: 23764300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.